Conclusion:
We think that Methylene Blue as an inexpensive ubiquitously available medication, has a considerable potential to be considered in treatment of SARS COV2.
We did not have a rapid access to set-up of a clinical study and it was prudent to share the idea with scientific community as soon as possible in this special situation.
Paradoxical and unexpected effects have been observed in Methylene Blue administration in other diseases if not meticulously done. Adverse reaction may happen in patients with a history of serotonergic medications as anti- depressants which may specially be prevalent these days(27). So any clinical step must be taken cautiously. In the other hand we must know that we are in a scrambling global health emergency and too much obsessive methodology may leave us with many dead patients to treat at the end of the day.
1. van de Veerdonk F, Netea MG, van Deuren M, van der Meer JW, de Mast Q, Bruggemann RJ, et al. Kinins and Cytokines in COVID-19: A Comprehensive Pathophysiological Approach. 2020.
2. Tolouian R, Vahed SZ, Ghiyasvand S, Tolouian A, Ardalan M. COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. Journal of Renal Injury Prevention. 2020;9(2).
3. Seyed-Mohammad Ghahestani M, Javad Mahmoudi P, Sakineh Hajebrahimi M, 4 , Amir-Babak Sioofy-Khojine D, PhD5,3,6*, Hanieh Salehi-Pourmehr P, Fatemeh Sadeghi-Ghyassi P, et al. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?
. Iranian journal of allergy asthma and immunology( In- Press publication). 2020.
4. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel medicine and infectious disease. 2020.
5. Ko W-C, Rolain J-M, Lee N-Y, Chen P-L, Huang C-T, Lee P-I, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents. 2020.
6. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020.
7. Lim J, Jeon S, Shin H-Y, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean medical science. 2020;35(6).
8. Alhenc-Gelas F, Drueke TB. Blockade of SARS-CoV-2 infection by recombinant soluble ACE2. Kidney International. 2020.
9. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-4.
10. Santos R, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J endocrinol. 2013;216(2):R1-R17.
11. Liu Q, Zhou Y-h, Yang Z-q. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cellular & molecular immunology. 2016;13(1):3-10.
12. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16-32.
13. Seyed-Mohammad Ghahestani M, Javad Mahmoudi P, Sakineh Hajebrahimi M, 4 , Amir Babak Sioofy Khojine D, PhD5,3,6*, Hanieh Salehi-Pourmehr P, Fatemeh Sadeghi-Ghyassi P, et al. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?. Iranian journal of allergy asthma and immunology( In- Press publication). 2020.
14. Read R. Flawed methods in “COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism”. 2020.
15. Siehr S, Stuth E, Tweddell J, Hoffman G, Troshynski T, Jones D, et al. Hypersensitivity reactions to aprotinin re-exposure in paediatric surgery. European journal of cardio-thoracic surgery. 2010;37(2):307-11.
16. Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G. Interactions among ACE, kinins and NO. Cardiovascular research. 1999;43(3):549-61.
17. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, et al. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. The Journal of clinical investigation. 2005;115(8):2099-107.
18. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(4):697-705.
19. Rhaleb N-E, Dion S, Barabé J, Rouissi N, Jukic D, Drapeau G, et al. Receptors for kinins in isolated arterial vessels of dogs. European journal of pharmacology. 1989;162(3):419-27.
20. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochemical pharmacology. 1993;45(2):367-74.
21. Yu B, Jin C, Zhang J, Wu H, Zhou X, Yao H, et al. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for the COVID-19 outbreak. 2020.
22. Henry M, Summa M, Patrick L, Schwartz L. A cohort of cancer patients with no reported cases of SARS-CoV-2 infection: the possible preventive role of Methylene Blue. Substantia. 2020:888-.
23. Galili Y, Kluger Y, Mianski Z, Iaina A, Wollman Y, Marmur S, et al. Methylene blue–a promising treatment modality in sepsis induced by bowel perforation. European surgical research. 1997;29(5):390-5.
24. Kwok ES, Howes D. Use of methylene blue in sepsis: a systematic review. Journal of intensive care medicine. 2006;21(6):359-63.
25. Umbrello M, Gardinali M, Ottolina D, Zanforlin G, Iapichino G. Systemic capillary leak syndrome: is methylene blue the silver bullet? Case reports in critical care. 2014;2014.
26. Floyd RA, Schinazi RF. Antiviral therapy using thiazine dyes. Google Patents; 2002.
27. Hencken L, To L, Ly N, Morgan JA. Serotonin syndrome following methylene blue administration for vasoplegic syndrome. Journal of cardiac surgery. 2016;31(4):208-10.